Author: admin

• Wondering if Eni’s recent run puts the stock at a discount or if the best value days are already behind it? You’re not alone, as investors everywhere are asking the same question right now.

• Eni’s share price has climbed 19.8% so far this year and 29.1% over the past 12 months, indicating renewed optimism and possible growth ahead.

• Much of this excitement has been fueled by recent positive developments in the energy sector, including moves toward cleaner production and new international projects. News highlighting Eni’s investment in low-carbon initiatives and overseas exploration has caught investors’ attention and contributed to the stock’s upward momentum.

• On the valuation front, Eni scores a 3 out of 6 based on our undervaluation checks. Next, we will explore the methods behind that score and provide insights to help better understand Eni’s real value.

Eni delivered 29.1% returns over the last year. See how this stacks up to the rest of the Oil and Gas industry.

The Discounted Cash Flow (DCF) model estimates a company’s value by projecting its future cash flows and discounting them back to today’s value. This approach helps investors gauge the present worth of all expected future cash the business will generate, using current financial data and reasonable growth assumptions.

For Eni, the most recent Free Cash Flow stands at approximately €4.40 billion. According to analyst consensus and Simply Wall St extrapolations, these cash flows are forecast to grow moderately, with projections reaching roughly €5.19 billion by 2028 and continuing upwards through 2035. Early estimates rely on analyst forecasts, while later years use logical estimates based on prevailing growth trends in the sector.

Using these inputs, the DCF analysis values Eni at an intrinsic fair value of €22.02 per share. This suggests that the current market price is about 26.7 percent below what the company’s future cash flows are worth today, indicating the stock is significantly undervalued according to this model. For investors seeking growth and value, this assessment may indicate a promising entry point.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Eni is undervalued by 26.7%. Track this in your watchlist or portfolio, or discover 920 more undervalued stocks based on cash flows.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Eni.

The Price-to-Earnings (PE) ratio is a well-known method used to value profitable companies like Eni, as it connects the market price to the company’s actual earnings. This metric is especially relevant for established businesses with positive earnings, offering a straightforward way to compare value across the sector.

It’s important to remember that what counts as a “normal” or “fair” PE ratio can change depending on growth prospects and perceived risk. Companies expected to grow rapidly or those considered safer investments typically command higher PE ratios, while riskier or slower-growing firms usually see lower multiples.

Currently, Eni trades at a PE ratio of 18.7x, which is higher than both the industry average of 13.3x and the peer group average of 13.1x. At first glance, this might suggest Eni is more expensive than its rivals. However, simply comparing these averages does not tell the whole story. This is where Simply Wall St’s “Fair Ratio” comes in. The Fair Ratio, calculated at 21.5x for Eni, incorporates not just earnings but also factors like Eni’s growth outlook, profitability, risk profile, industry position, and its size in the market.

The Fair Ratio is a more holistic metric than industry or peer comparisons because it is tuned to Eni’s specific fundamentals, rather than being based on broader or less relevant companies. In this case, Eni’s actual PE ratio is about 2.8x below its Fair Ratio, indicating that, on this measure, the stock could be considered undervalued.

Result: UNDERVALUED

PE ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1443 companies where insiders are betting big on explosive growth.

Earlier we mentioned that there is an even better way to understand valuation, so let’s introduce you to Narratives. A Narrative is your own story about a company that connects what you believe about its business, industry changes, and trends with the actual numbers, such as fair value, future revenue, earnings, and profit margins.

Rather than simply relying on historic data or a single metric, Narratives let you link what is happening in the real world to a financial forecast and, ultimately, to what you believe is a fair price for the stock. This approach is accessible and easy to use for investors of all experience levels on Simply Wall St, right from the Community page used by millions.

Narratives empower you to decide when to buy or sell, making it simple to see at a glance how your fair value compares to the current price. Because they update automatically with new information, such as news, earnings reports, or industry developments, your view is always relevant and up to date.

For example, when it comes to Eni, some investors are optimistic and see a fair value as high as €17.5, while others, more cautious, estimate just €13.5. This illustrates how Narratives capture the range of real investor perspectives and make stock decisions more intuitive and personal.

Do you think there’s more to the story for Eni? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ENI.MI.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Story Continues

Story Continues

Story Continues

What makes a “normal” P/E ratio? It is shaped by the company’s expected earnings growth, its profit stability, and the level of risk investors perceive in the business and industry. Fast-growing, lower-risk companies generally command higher P/E multiples, while mature or riskier firms often trade at lower levels.

Deutsche Bank currently trades at a P/E of 11.3x. This is below the Capital Markets industry average of 14.7x and also sits under the peer average of 17.8x. However, there is a more tailored benchmark to consider: the Simply Wall St Fair Ratio. For Deutsche Bank, the Fair Ratio is estimated at 26.5x, a proprietary metric that blends the company’s earnings outlook, profit margins, industry positioning, market capitalization, and risk factors. The Fair Ratio provides a more nuanced context than peers or industry averages alone because it takes into account how Deutsche Bank’s unique mix of strengths and risks affect its intrinsic value.

When comparing Deutsche Bank’s actual P/E of 11.3x to its Fair Ratio of 26.5x, the stock appears significantly undervalued, suggesting that the current price does not fully reflect the bank’s improved earnings prospects and position within its sector.

Result: UNDERVALUED

PE ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1443 companies where insiders are betting big on explosive growth.

Earlier we mentioned that there is an even better way to understand valuation, so let’s introduce you to Narratives.

A Narrative is simply your story behind the numbers, an investor’s personal perspective on a company’s future that connects what you believe will happen next with a specific financial forecast and a fair value estimate. Narratives make investing more approachable because they link Deutsche Bank’s unique business drivers, key risks, and competitive advantages directly to concrete figures such as projected earnings, revenues, profit margins, and assumed valuation multiples. This approach helps transform complex financials into a story you can take action on.

This tool, available to millions of users on Simply Wall St’s Community page, empowers you to create, adjust, and follow Narratives that reflect your own views or those of other investors. By continuously updating with the latest earnings, news, and company events, Narratives allow you to compare your estimated fair value with Deutsche Bank’s current share price and decide when you think it is time to buy, hold, or sell.

For example, some investors’ Narratives assume Deutsche Bank will trade at €35.00 per share thanks to strong earnings and revenue growth. Others build a more cautious scenario with a fair value of just €10.93, reflecting higher risk or slower profit improvement.

Do you think there’s more to the story for Deutsche Bank? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include DBK.DE.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Welcome to OncLive®’s OncFive!

Every week, we bring you a quick roundup of the 5 top stories from the world of oncology—ranging from pivotal regulatory decisions to key pipeline updates to expert insights on breakthroughs that are moving the needle in cancer care. This resource is designed to keep you informed on the latest updates in the space, in just a matter of minutes.

Here’s what you may have missed this week:

The FDA approved durvalumab (Imfinzi) for use in combination with FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) as neoadjuvant and adjuvant treatment, followed by single-agent durvalumab, for adult patients with resectable gastric and gastroesophageal junction (GEJ) adenocarcinoma.¹

The regulatory decision was supported by findings from the phase 3 MATTERHORN trial (NCT04592913), which showed durvalumab plus FLOT reduced the risk of disease progression, recurrence, or death by 29% compared with FLOT alone; The median event-free survival (EFS) was not reached (95% CI, 40.7-not estimable [NE]) with durvalumab vs 32.8 months (95% CI, 27.9-NE) with FLOT alone. (HR, 0.71; 95% CI, 0.58-0.86; P < .001). The pathological complete response rate was 19.2% (95% CI, 15.7%-23.0%) in the durvalumab arm vs 7.2% (95% CI, 5.0%-9.9%) in the FLOT alone arm (P < .001).

The FDA has granted priority review to a new drug application (NDA) seeking the approval of sonrotoclax (BGB-11417) for the treatment of adult patients with relapsed or refractory MCL who have received prior treatment with a BTK inhibitor.²

The NDA is supported by findings from the phase 1/2 BGB-11417-201 trial (NCT05471843), which met its primary end point of overall response rate (ORR) per independent review committee (IRC) and showed clinically meaningful responses among 125 adult patients with relapsed/refractory disease previously treated with a BTK inhibitor. Full data from the study that support the NDA will be presented at the 2025 ASH Annual Meeting.

Treatment with Sacituzumab tirumotecan (sac-TMT; SKB264/MK-2870) in combination with pembrolizumab (Keytruda) yielded a statistically significant and clinically meaningful improvement in progression-free survival (PFS) vs pembrolizumab alone in patients with PD-L1–positive advanced non–small cell lung cancer (NSCLC), meeting the primary end point of the phase 3 OptiTROP-Lung05 trial (NCT06448312).³

Overall survival also trended in favor of the sac-TMT regimen, per independent data monitoring committee assessment. Based on these findings, an NDA could be submitted to the Center for Drug Evaluation of the National Medical Products Administration in China seeking the approval of sac-TMT in this indication.

Treatment with subcutaneous toripalimab (JS001sc) in combination with chemotherapy generated comparable pharmacokinetics (PK) compared with intravenous (IV) toripalimab (Loqtorzi) plus chemotherapy in patients with recurrent or metastatic nonsquamous non–small cell lung cancer (NSCLC), meeting the primary end points of the phase 3 JS001sc-002-III-NSCLC trial (NCT06505837).⁴

The study met both its primary end points: observed serum C_trough concentration at cycle 1 and model-predicted area under the concentration time curve from 0 to 21 days at cycle 1. Findings also demonstrated that subcutaneous toripalimab produced comparable efficacy and safety outcomes compared with the IV formulation. Full trial data will be presented at an upcoming international medical conference.

The European Commission approved lisocabtagene maraleucel (Breyanzi; liso-cel) for the treatment of adult patients with relapsed or refractory MCL following at least 2 prior lines of systemic therapy, including a BTK inhibitor.⁵

This regulatory decision is supported by data from the MCL cohort of the phase 1 TRANSCEND NHL 001 trial (NCT02631044), which showed that liso-cel generated an ORR of 82.7% (95% CI, 72.7%-90.2%) and a complete response rate of 71.6% (95% CI, 60.5%-81.1%). The median time to first response was 0.95 months, and 41.2% (95% CI, 29.2%-52.9%) of patients remained in response at 24 months.

References

1. FDA approves durvalumab for resectable gastric or gastroesophageal junction adenocarcinoma. FDA. November 25, 2025. Accessed November 26, 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-resectable-gastric-or-gastroesophageal-junction-adenocarcinoma
2. U.S. FDA grants priority review to sonrotoclax for the treatment of relapsed or refractory mantle cell lymphoma. News release. BeOne Medicines. November 26, 2025. Accessed November 26, 2025. https://ir.beonemedicines.com/news/us-fda-grants-priority-review-to-sonrotoclax-for-the-treatment-of-relapsed-or-refractory-mantle/786f1dad-0c9f-492e-9fce-f9ceadd24989
3. Kelun-Biotech announces phase 3 trial of sac-TMT in combination with Keytruda (pembrolizumab) as first-line treatment for PD-L1–positive NSCLC met primary endpoint. News Release. PR Newswire. November 24, 2025. Accessed November 26, 2025. https://www.prnewswire.com/news-releases/kelun-biotech-announces-phase-iii-trial-of-sac-tmt-in-combination-with-keytruda-pembrolizumab-as-first-line-treatment-for-pd-l1-positive-nsclc-met-primary-endpoint-302624279.html
4. Junshi Biosciences announces primary endpoints met in JS001sc’s phase 3 study for the 1st-line treatment of NSQ-NSCLC. News release. Shanghai Junshi Biosciences. November 24, 2025. Accessed November 26, 2025. https://www.globenewswire.com/news-release/2025/11/25/3193998/0/en/Junshi-Biosciences-Announces-Primary-Endpoints-Met-in-JS001sc-s-Phase-3-Study-for-the-1ST-line-Treatment-of-NSQ-NSCLC.html
5. Bristol Myers Squibb receives approval from the European Commission to expand use of CAR T cell therapy Breyanzi for relapsed or refractory mantle cell lymphoma. News release. Bristol Meyers Squibb. November 24, 2025. Accessed November 26, 2025. https://news.bms.com/news/corporate-financial/2025/Bristol-Myers-Squibb-Receives-Approval-from-the-European-Commission-to-Expand-Use-of-CAR-T-Cell-Therapy-Breyanzi-for-Relapsed-or-Refractory-Mantle-Cell-Lymphoma/default.aspx